Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?
Anemia of chronic disease
Chronic kidney disease
Inflammation
Interleukin-6
Ziltivekimab
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
12
03
2024
accepted:
17
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
Anemia of chronic kidney disease is a multifactorial condition secondary to various etiologies, including nutritional deficiencies, chronic inflammation, erythropoietin deficiency or resistance, bone marrow suppression, iron deficiency and adverse drug effects. The major therapeutic intervention for anemia among chronic kidney disease patients is erythropoiesis-stimulating agents. However, a limitation of erythropoiesis-stimulating agents is the risk for thromboembolic events, hypertension, seizures, solid organ malignancies and hyporesponsiveness. A novel interleukin-6 monoclonal antibody, ziltivekimab, has been evaluated for managing anemia in chronic kidney disease patients in pilot clinical trials with promising outcomes, including an improvement in hemoglobin levels and reduction of inflammatory parameters. These trials have shown that ziltivekimab does not increase the risk for cytopenia or infectious complications as has been described for other interleukin-6-targeting monoclonal antibodies, like tocilizumab. Furthermore, potentially beneficial effects on serum lipid profile have been reported, leading to the hypothesis of a favorable impact of the drug on atherosclerotic complications. In addition, ziltivekimab has shown efficacy in improving anemia parameters, including hemoglobin levels and iron studies. Ziltivekimab deserves full scale clinical development, and to this aim, large-scale clinical trials are under way.
Identifiants
pubmed: 39453604
doi: 10.1007/s40620-024-02117-0
pii: 10.1007/s40620-024-02117-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Italian Society of Nephrology.
Références
Kovesdy CP, Davis JR, Duling I, Little DJ (2023) Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999–2018 national health and nutrition examination survey. Clin Kidney J 16:303–311
pubmed: 36755833
Bishaw F, Belay Woldemariam M, Mekonen G, Birhanu B, Abebe A (2023) Prevalence of anemia and its predictors among patients with chronic kidney disease admitted to a teaching hospital in Ethiopia: a hospital-based cross-sectional study. Med (Baltim) 102:e31797
Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23:1631–1634
pubmed: 22935483
pmcid: 3458456
Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A (2010) Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1–12
pubmed: 19816014
Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayer WC, Wheeler DC (2023) Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 104:655–680
pubmed: 37236424
Santos EJF, Dias RSC, Lima JFB, Salgado Filho N, Miranda Dos Santos A (2020) Erythropoietin resistance in patients with chronic kidney disease: current perspectives. Int J Nephrol Renovasc Dis 13:231–237
pubmed: 33116754
pmcid: 7549651
Schoener B, Borger J (2024) Erythropoietin stimulating agents. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC, St Petersburg
Xu B, Liu S, Li Y, Zhao L, Song X, Chen T (2021) Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. Clin Kidney J 14:2444–2445
pubmed: 34754441
pmcid: 8573001
Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C (2021) Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl 36:1616–1628
Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M (2011) Renal anemia of inflammation: the name is self-explanatory. Blood Purif 32:220–225
pubmed: 21829013
Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M (2016) Novel masters of erythropoiesis: hypoxia inducible factors and recent advances in anemia of renal disease. Blood Purif 42:160–167
pubmed: 27318465
Zoccali C, Mallamaci F (2023) Innate immunity system in patients with cardiovascular and kidney disease. Circ Res 132:915–932
pubmed: 37053283
Ortiz A (2022) RICORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J 15:372–387
pubmed: 35211298
Ortiz A, Wanner C, Gansevoort R (2023) Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the council of the European renal association. Clin Kidney J 16:403–407
pubmed: 36865018
ERA-EDTA Council, ERACODA Working Group (2021) Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transpl 36:87–94
Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, Ortiz A (2021) Role of klotho in the development of essential hypertension. Hypertension 77:740–750
pubmed: 33423524
Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, Fouque D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Parati G, Rossignol P, Wiecek A, London G (2017) The systemic nature of CKD. Nat Rev Nephrol 13:344–358
pubmed: 28435157
Tonelli M, Wiebe N, Manns BJ, Klarenbach SW, James MT, Ravani P, Pannu N, Himmelfarb J, Hemmelgarn BR (2018) Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open 1:e184852
pubmed: 30646392
pmcid: 6324421
Wyld MLR, Morton RL, Clayton P, Wong MG, Jardine M, Polkinghorne K, Chadban S (2019) The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Qual Life Res 28:2081–2090
pubmed: 30937731
McElvaney OJ, Curley GF, Rose-John S, McElvaney NG (2021) Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med 9:643–654
pubmed: 33872590
pmcid: 8051931
Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335–345
pubmed: 32327746
pmcid: 7178926
Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, Zhang X, Peng A, Najjar R, Williamson S, Myers C, Sethi S, Lim K, Choi J, Gillespie M, Tang J, Jordan SC (2022) Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transpl 22:1133–1144
Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A (2022) Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. Trials 23:1042
pubmed: 36550562
pmcid: 9772593
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH (2021) Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind placebo controlled trial. J Am Soc Nephrol 32:211–222
pubmed: 33272965
Nowak KL, Kakkar R, Devalaraja M, Lo L, Park W, Gobburu J, Kling D, Davidson M, Chonchol M (2021) A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney 360 2:224–235
pubmed: 35373026
Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, López-Otín C (2009) Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 94:840–849
pubmed: 19377077
pmcid: 2688576
Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, Zabaneh D, Hoggart C, Bayele H, McCarthy MI, Peltonen L, Freimer NB, Srai SK, Maxwell PH, Sternberg MJ, Ruokonen A, Abecasis G, Jarvelin MR, Scott J, Elliott P, Kooner JS (2009) Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 41:1170–1172
pubmed: 19820698
pmcid: 3178047
Pergola PE, Davidson M, Jensen C, Mohseni Zonoozi AA, Raj DS, Andreas Schytz P, Tuttle KR, Perkovic V (2023) Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3–5: an analysis of a randomized trial (RESCUE). J Am Soc Nephrol. https://doi.org/10.1681/ASN.0000000000000245
doi: 10.1681/ASN.0000000000000245
pubmed: 38088558
Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transpl 28:1346–1359
Drüeke TB, Parfrey PS (2012) Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 82:952–960
pubmed: 22854645
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032
pubmed: 19880844
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363:1146–1155
pubmed: 20843249
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590
pubmed: 9718377
Lindenblatt N, Menger MD, Klar E, Vollmar B (2007) Darbepoetin-alpha does not promote microvascular thrombus formation in mice: role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 27:1191–1198
pubmed: 17347485
Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380:447–458
pubmed: 30365356
Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, Pérez-Fernández M, Ortiz A (2019) Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol 39:1938–1966
pubmed: 31412740
Afsar B, Turkmen K, Covic A, Kanbay M (2014) An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014:767424
pubmed: 24734178
pmcid: 3964836
Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129–2138
pubmed: 19942084
pmcid: 2834169
Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:2060–2069
pubmed: 34015342
Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, Schröder JO, Gouni-Berthold I, Berthold HK, Krone W, Rose-John S, Schreiber S, Laudes M (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 56:1034–1042
pubmed: 25713100
pmcid: 4409280
Fernandez-Prado R, Perez-Gomez MV, Ortiz A (2020) Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 13:753–757
pubmed: 33123354
pmcid: 7577764
Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H (2023) Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol 82:279–285
pubmed: 37211246
Chertow GM, Chang AM, Felker GM, Heise M, Velkoska E, Fellström B, Charytan DM, Clementi R, Gibson CM, Goodman SG, Jardine M, Levin A, Lokhnygina Y, Mears J, Mehran R, Stenvinkel P, Wang A, Wheeler DC, Zoccali C, Ridker PM, Mahaffey KW, Tricoci P, Wolf M (2024) IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. https://doi.org/10.1038/s41591-024-03043-1
doi: 10.1038/s41591-024-03043-1
pubmed: 38961226
pmcid: 11333268
Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:304–311
pubmed: 12633573
Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M (2010) Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 69:741–746
pubmed: 19433409
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA (2021) A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 32:708–722
pubmed: 33443079
Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A (2022) Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep 7:720–731
pubmed: 35497778
pmcid: 9039906
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131
pubmed: 28845751
Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 162:597–605
pubmed: 21982649
Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T (2012) Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748
pubmed: 23129601
Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH (2018) Inhibition of Interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414
pubmed: 29793629
Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, Yates DP, Beste MT, Libby P, Ridker PM, Steensma DP (2023) Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv 7:7471–7484
pubmed: 37934948
pmcid: 10758744
Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jorgensen T, Danesh J (2014) Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35:578–589
pubmed: 24026779
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424
pubmed: 7880233
Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG (2022) Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J 43:4832–4844
pubmed: 35943897